PR Newswire - Accro Bioscience Announces $50 Million Series C Fi...
Financing led by OrbiMed with participation from TCGX, LAV, Cenova Capital and existing investors SCGC and Oriza Proceeds will advance multi-asset pipeline including AC-101, a leading RIPK2 inhibitor...
Read More

ภาษาไทย
English